Jun 12 |
Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation'
|
Jun 11 |
Oil prices, National Amusement ends Skydance talks: Market Domination
|
Jun 11 |
Eli Lilly's new Alzheimer's treatment could 'lift' drug market
|
Jun 11 |
FOMC meeting, Ford vice chair on hybrid growth: Morning Brief
|
Jun 11 |
Eli Lilly Continues To Climb As Alzheimer's Drug Gains FDA Approval
|
Jun 11 |
Eli Lilly: The Road To Approval Of Donanemab Is Open
|
Jun 11 |
Wall Street’s most overbought stocks include NVDA, COST, LLY, and others
|
Jun 11 |
FDA Advisers Like Lilly’s Alzheimer’s Drug. It’s Good News for Biogen.
|
Jun 11 |
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
|
Jun 11 |
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
|